AstraZeneca sheds pension risk; Allergan, Sanofi, Shire, Gedeon Richter slapped by ABPI for unprofessional conduct;

@FiercePharma: Whoa: Amy Schulman is out, rather abruptly, at Pfizer. She was one of the three division chiefs chosen by CEO Ian Read earlier this year. | Follow @FiercePharma

@EricPFierce: Teva renegs on plans to build a new API plant in India. Story from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: Pfizer names Albert Bourla Group President; Vaccines, Oncology and Consumer Healthcare Business. Release | Follow @CarlyHFierce

> Chile's CFR Pharmaceuticals, which has made a $1.2 billion offer to buy South Africa's struggling drugmaker Adcock Ingram, has accused the state pension fund of protectionism for opposing its bid. Story

> The Bristol-Myers Squibb Foundation is handing out $3.28 million in grants to a variety of groups that work on mental health issues of U.S. military members who served in Afghanistan and Iraq. Release

> Pfizer ($PFE) and Germany's Siemens ($SI) have struck a deal to work on in vitro diagnostic tests. Story

> The trustee for the AstraZeneca Pension Fund is passing the £2.5 billion in pension fund liabilities to reinsurance firms through a longevity swap with Deutsche Bank. Story

> Workers at Pfizer's plant in Newbridge, Ireland, have until Jan. 20 to apply for voluntary redundancy before the company starts laying off 150 workers. Story

> Makers of antibacterial soaps have been ordered to come clean on how effective--and potentially harmful--their products are. Story

> Teva Pharmaceutical Industries' ($TEVA) vice chairman Moshe Many is leaving his position with the company at the end of the year, two months after CEO Jeremy Levin left over disagreements with the board. Story

Medical Device News

@FierceMedDev: TruTouch Technologies (biometric alcohol sensor) names Marathon's Bruce Berger CEO. Release | Follow @FierceMedDev

@MarkHFierce: In an interesting twist, ViewRay's new $30M round includes an investment from a Chinese distributor. Story | Follow @MarkHFierce

@MichaelGFierce: Alnylam begins PhII trial for amyloidosis RNAi treatment. Item from FierceDrugDelivery | Follow @MichaelGFierce

@GalenMoore: Boston Scientific recruits a veteran Silicon Valley investor amid its M&A push. More | Follow @GalenMoore

> Belgium's Cardio3 Biosciences gets $5.5M to advance heart catheter, stem cell treatment. Item

> SynCardia's $14M infusion will fuel formal testing of a smaller-sized heart implant. Story

> Myriad contends with investors anxious over possible CMS Dx reimbursement declines. More

Biotech News

@FierceBiotech: Biogen Idec preps for a big leap into the anti-TNF blockbuster biosimilars market. More | Follow @FierceBiotech

@JohnCFierce: "Amy Schulman and Pfizer have agreed to separate." What, no retirement? More | Follow @JohnCFierce

@DamianFierce:  Amgen keeps with the PCSK9 pack in its first Phase III results for evolocumab. News | Follow @DamianFierce

@EmilyMFierce: Researchers find a possible drug target for undruggable melanoma. Story | Follow @EmilyMFierce

> Organogenesis slashes its R&D staff as Medicare preps a big price cut. More

> Imperial spearheads $28M round for an upstart in the antibody fragment field. Article

Pharma Manufacturing News

> China rounds up hundreds in crackdown against drug counterfeiters. More

> Novartis' OTC recall is tied to a contractor this time. Story

> Novartis to shed Alcon plant, 300 jobs next year. News

> What's a makeover cost these days? For AstraZeneca's distribution hub, $100M. Article

> Teva reneges on its proposal to build a $141M API plant in India. Report

> Wales fines companies £120,000 for worker accidents. Item

Biotech Research News

> Congressional budget deal would ease NIH sequester cuts. Story

> Report: Life science research needs standards to curb irreproducible studies. More

> CIRM awards $61M for cancer research. Item

> Researchers find possible drug targets for undruggable melanomas. News

> Blood vessel breakdown in the brain may be linked to Alzheimer's. Report

> Glaxo compound slows Lou Gehrig's disease in animal models. Article

And Finally... U.S.-based Allergan ($AGN), Ireland-based Shire Pharmaceuticals ($SHPG), Hungary-based Gedeon Richter and France-based Sanofi ($SNY) have all been found to have violated the U.K.'s Association of the British Pharmaceutical Industry (ABPI) Code of Practice and brought discredit upon, and reduced confidence in, the pharmaceutical industry. Story

Suggested Articles

In previously untreated nonsquamous NSCLC, a Tyvyt-chemo combo beat chemo alone at stalling the time to tumor progression or death.

It’s been a big year for Bristol's Opdivo-Yervoy combo in lung cancer, but with new mesothelioma data in hand, the duo isn’t done making headlines.

A third spinal muscular atrophy treatment option is set to debut with the FDA’s approval for Roche’s Evrysdi, formerly known as risdiplam.